Cancer BiologybioRxivPreprint
In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer
Matthew Decker, Benjamin J. Huang, Timothy B. Ware…·Kevin Shannon
This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.
3 citations